Review
BibTex RIS Cite

Chemopreventive Effects of Nonsteroidal Antiinflammatory Drugs

Year 2025, Volume: 15 Issue: 2, 315 - 320, 22.05.2025

Sıla Ölmez , Tolga Köşeci , Erkan Kozanoglu

https://doi.org/10.33631/sabd.1386939

Abstract

Cancer is a common disease with high mortality rates for both sexes worldwide. Therefore, the development of new strategies for the prevention and treatment of cancer is of great importance. Non-steroidal anti-inflammatory drugs are widely used in the treatment of acute and chronic diseases due to their pain relieving, antipyretic and anti-inflammatory effects. These drugs are routinely prescribed in medical specialties such as physical medicine and rehabilitation, rheumatology, orthopedics and algology. However, in recent years, there have been many studies suggesting that non-steroidal anti-inflammatory drugs not only provide pain relief and inflammation control but may also have the potential to exert chemopreventive effects in various cancer types. The effects of non-steroidal anti-inflammatory drugs on different mechanisms to inhibit cancer cell growth, reduce metastasis and prevent tumor development are being investigated. This review aims to provide a comprehensive review of the current literature on the potential chemopreventive effects of non-steroidal anti-inflammatory drugs against various types of cancer and their mechanisms of anticancer action.

Keywords

Nonsteroidal antiinflammatory drugs NSAID’s Carcinogenesis Chemoprevention

References

  • Hilal-Dandan R, Brunton LL, Goodman LS. Goodman and Gilman's manual of pharmacology and therapeutics. 2nd ed. New York: McGraw-Hill; 2014.
  • Saka-Herran C, Jane-Salas E, Estrugo-Devesa A, Lopez-Lopez J. Head and neck cancer and non-steroidal anti-inflammatory drugs: systematic review and meta-analysis. Head Neck. 2021; 43(5): 1664-82.
  • Lapumnuaypol K, Tiu A, Thongprayoon C, Wijarnpreecha K, Ungprasert P, Mao MA et.al. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. QJM. 2019; 112(6): 421-7.
  • Tudor DV, Bâldea I, Olteanu DE, Fischer-Fodor E, Piroska V, Lupu M et. al. Celecoxib as a valuable adjuvant in cutaneous melanoma treated with trametinib. International Journal of Molecular Sciences. 2021; 22 (9): 4387.
  • Liu X, Wu Y, Zhou Z, Huang M, Deng W, Wang Y et. al. Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the mirna-145/tgfbr2/smad3 axis. International Journal of Molecular Medicine. 2019; 44(2): 683-93.
  • Ma S, Guo C, Sun C, Han T, Zhang H, Qu G, et.al. Aspirin use and risk of breast cancer: a meta-analysis of observational studies from 1989 to 2019. Clin Breast Cancer. 2021; 21(6): 552-65.
  • Chiang SL, Velmurugan BK, Chung CM, Lin SH, Wang ZH, Hua CH, et.al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep. 2017; 7(1): 6235.
  • Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018; 8(7): e021869.
  • Zhang J, Wu H, Wang R. Effect of nonsteroidal anti-inflammatory drugs on barrett's esophagus risk: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021; 45(3): 101552.
  • Garcia-Rodriguez LA, Soriano-Gabarro M, Vora P, Cea-Soriano L. Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study in the United Kingdom using The Health Improvement Network. Int J Cancer. 2020; 147(9): 2394-404.
  • Arai J, Niikura R, Hayakawa Y, Kawahara T, Honda T, Hasatani K, et.al. Chemoprevention of oesophageal squamous-cell carcinoma and adenocarcinoma: a multicentre retrospective cohort study. Digestion. 2022; 103(3): 192-204.
  • Shami JJP, Zhao J, Pathadka S, Wan EYF, Blais JE, Vora P, et. al. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022; 12(2): e050510.
  • Holmberg D, Gottlieb-Vedi E, Hedberg J, Lindblad M, Mattsson F, Lagergren J. Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study. BMC Cancer. 2023; 23(1): 375.
  • Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie SH, et. al. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma. Gastric Cancer. 2022; 25(3): 652-8.
  • Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, et. al. Combination of sulindac and bexarotene for prevention of intestinal carcinogenesis in familial adenomatous polyposis. Cancer Prev Res (Phila). 2021; 14(9): 851-62.
  • Bowen CM, Deng N, Reyes-Uribe L, Parra ER, Rocha P, Solis LM, et. al. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in lynch syndrome colorectal mucosa. Front Immunol. 2023; 14: 1162669.
  • Zhang Y , Chan AT, Meyerhardt JA, Giovannucci EL. Timing of aspirin use in colorectal cancer chemoprevention: a prospective cohort study. J Natl Cancer Inst. 2021; 113(7): 841-51.
  • Figueiredo JC, Jacobs EJ, Newton CC, Guinter MA, Cance WG, Campbell PT. Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis. J Natl Cancer Inst. 2021; 113(7): 833-40.
  • Diao F, Cai S. Aspirin-based chemoprevention of colorectal cancer: the role for gut microbiota. Cancer Commun (Lond). 2020; 40(11): 633-5.
  • Tomic T, Dominguez-Lopez S, Barrios-Rodriguez R. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: a systematic review and meta-analysis. Cancer Epidemiol. 2019; 58: 52-62.
  • He P, Yang C, Ye G, Xie H, Zhong W. Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis. Colorectal Dis. 2019; 21(4): 417-26.
  • Wang Y, Wang M, Liu C, Wang W, Shi J, Dang S. Aspirin use and the risk of hepatocellular carcinoma: a meta-analysis. J Clin Gastroenterol. 2022; 56(7): e293-e302.
  • Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis c virus infection. Clin Gastroenterol Hepatol. 2020; 18(12): 2784-92 e7.
  • Liao YH, Hsu RJ, Wang TH, Wu CT, Huang SY, Hsu CY, et.al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterol. 2020; 20(1): 6.
  • Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021; 54(4): 356-67.
  • Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. Eur J Clin Pharmacol. 2022; 78(4): 647-56.
  • Marcano-Bonilla L, Schleck CD, Harmsen WS, Sadr-Azodi O, Borad MJ, Patel T, et.al. Aspirin, statins, non-aspirin nsaids, metformin, and the risk of biliary cancer: a Swedish population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2022; 31(4): 804-10.
  • Sun J, Li Y, Liu L, Jiang Z, Liu G. Aspirin use and pancreatic cancer risk: a systematic review of observational studies. Medicine (Baltimore). 2019; 98(51): e18033.
  • Ye S, Lee M, Lee D, Ha EH, Chun EM. Association of long-term use of low-dose aspirin as chemoprevention with risk of lung cancer. JAMA Netw Open. 2019; 2(3): e190185.
  • Yu SY, Ip MS, Li X, Cheung KS, Ren QW, Wu MZ, et.al. Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: a cohort study. PLoS Med. 2022; 19(1): e1003880.
  • Bittoni MA, Carbone DP, Harris RE. Ibuprofen and fatal lung cancer: a brief report of the prospective results from the third national health and nutrition examination survey (NHANES III). Mol Clin Oncol. 2017; 6(6): 917-20.
  • Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of cox-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018; 11: 721-30.
  • Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, et.al. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the epidemiology of endometrial cancer consortium. Ann Oncol. 2019; 30(2): 310-6.
  • Sperling CD, Verdoodt F, Aalborg GL, Dehlendorff C, Friis S, Kjaer SK. Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study. Int J Epidemiol. 2020; 49(1): 330-7.
  • Sperling CD, Verdoodt F, Aalborg GL, Dehlendorff C, Friis S, Kjaer SK. Non-aspirin nsaid use and mortality of endometrial cancer. a nationwide cohort study. Cancer Causes Control. 2021; 32(5): 515-23.
  • Hurwitz LM, Pinsky PF, Huang WY, Freedman ND, Trabert B. Aspirin use and ovarian cancer risk using extended follow-up of the plco cancer screening trial. Gynecol Oncol. 2020; 159(2): 522-6.
  • Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, et.al. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (nhs/nhsii): a cohort study. Lancet Oncol. 2018; 19(8): 1107-16.
  • Wield AM, Walsh CS, Rimel BJ, Cass I, Karlan BY, Li AJ. Aspirin use correlates with survival in women with clear cell ovarian cancer. Gynecol Oncol Rep. 2018; 25: 78-81.
  • Liu J, Zheng F, Yang M, Wu X, Liu A. Effect of aspirin use on survival benefits of breast cancer patients: a meta-analysis. Medicine (Baltimore). 2021; 100(33): e26870.
  • Sherman ME, Vierkant RA, Kaggal S, Hoskin TL, Frost MH, Denison L, et.al. Breast cancer risk and use of nonsteroidal anti-inflammatory agents after a benign breast biopsy. Cancer Prev Res (Phila). 2020; 13(11): 967-76.
  • Mohammed A, Miller MS, Lubet RA, Suen CS, Sei S, Shoemaker RH, et.al. Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers. Cancer Prev Res (Phila). 2020; 13(3): 273-82.
  • Fan LL, Xie CP, Wu YM, Gu XJ, Chen YH, Wang YJ. Aspirin exposure and mortality risk among prostate cancer patients: a systematic review and meta-analysis. Biomed Res Int. 2019; 2019: 9379602.
  • Skriver C, Dehlendorff C, Borre M, Brasso K, Larsen SB, Tjonneland A, et.al. Associations of low-dose aspirin or other nsaid use with prostate cancer risk in the Danish diet, cancer and health study. Cancer Causes Control. 2020; 31(2): 139-51.
  • Broadfield LA, Marcinko K, Tsakiridis E, Zacharidis PG, Villani L, Lally JSV, et.al. Salicylate enhances the response of prostate cancer to radiotherapy. Prostate. 2019; 79(5): 489-97.
  • Shaji S, Smith C, Forget P. Perioperative nsaids and long-term outcomes after cancer surgery: a systematic review and meta-analysis. Curr Oncol Rep. 2021; 23(12): 146.

Nonsteroidal Antiinflamatuvar İlaçların Kemopreventif Etkileri

Year 2025, Volume: 15 Issue: 2, 315 - 320, 22.05.2025

Sıla Ölmez , Tolga Köşeci , Erkan Kozanoglu

https://doi.org/10.33631/sabd.1386939

Abstract

Kanser, dünya genelinde her iki cinsiyet için de yüksek mortalite oranlarına sahip ve yaygın olarak görülen bir hastalıktır. Bu sebeple, kanserin önlenmesi ve tedavisine yönelik yeni stratejilerin geliştirilmesi, büyük bir önem arz etmektedir. Non-steroidal antiinflamatuvar ilaçlar, ağrı kesici, ateş düşürücü ve inflamasyon önleyici etkileri nedeniyle, akut ve kronik hastalıkların tedavisinde yaygın olarak kullanılan ilaçlar arasında yer almaktadır. Bu ilaçlar, özellikle fiziksel tıp ve rehabilitasyon, romatoloji, ortopedi, algoloji gibi tıbbi branşlarda rutin olarak sıkça reçete edilmektedir. Bununla birlikte, son yıllarda non-steroidal antiinflamatuvar ilaçların sadece ağrı kesici etki ve inflamasyon kontrolü sağlamadıkları, aynı zamanda çeşitli kanser türlerinde kemopreventif etki gösterme potansiyeline sahip olabilecekleri yönünde birçok çalışma yapılmıştır. Non-steroidal antiinflamatuvar ilaçların kanser hücrelerinin büyümesini engellemeye, metastazı azaltmaya ve tümör gelişimini önlemeye yönelik farklı mekanizmalar üzerindeki etkileri araştırılmaktadır. Bu derleme, non-steroidal antiinflamatuvar ilaçların çeşitli kanser türlerine karşı potansiyel kemopreventif etkilerini ve antikanser etki mekanizmalarını ele alarak, bu konudaki güncel literatürü kapsamlı bir şekilde incelemeyi amaçlamaktadır.

Keywords

Nonsteroidal antiinflamatuvar ilaçlar NSAİİ Karsinogenez profilaksi

Ethical Statement

Bu çalışma için etik kurul onayı alınmasına gerek yoktur.

References

  • Hilal-Dandan R, Brunton LL, Goodman LS. Goodman and Gilman's manual of pharmacology and therapeutics. 2nd ed. New York: McGraw-Hill; 2014.
  • Saka-Herran C, Jane-Salas E, Estrugo-Devesa A, Lopez-Lopez J. Head and neck cancer and non-steroidal anti-inflammatory drugs: systematic review and meta-analysis. Head Neck. 2021; 43(5): 1664-82.
  • Lapumnuaypol K, Tiu A, Thongprayoon C, Wijarnpreecha K, Ungprasert P, Mao MA et.al. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. QJM. 2019; 112(6): 421-7.
  • Tudor DV, Bâldea I, Olteanu DE, Fischer-Fodor E, Piroska V, Lupu M et. al. Celecoxib as a valuable adjuvant in cutaneous melanoma treated with trametinib. International Journal of Molecular Sciences. 2021; 22 (9): 4387.
  • Liu X, Wu Y, Zhou Z, Huang M, Deng W, Wang Y et. al. Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the mirna-145/tgfbr2/smad3 axis. International Journal of Molecular Medicine. 2019; 44(2): 683-93.
  • Ma S, Guo C, Sun C, Han T, Zhang H, Qu G, et.al. Aspirin use and risk of breast cancer: a meta-analysis of observational studies from 1989 to 2019. Clin Breast Cancer. 2021; 21(6): 552-65.
  • Chiang SL, Velmurugan BK, Chung CM, Lin SH, Wang ZH, Hua CH, et.al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep. 2017; 7(1): 6235.
  • Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018; 8(7): e021869.
  • Zhang J, Wu H, Wang R. Effect of nonsteroidal anti-inflammatory drugs on barrett's esophagus risk: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021; 45(3): 101552.
  • Garcia-Rodriguez LA, Soriano-Gabarro M, Vora P, Cea-Soriano L. Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study in the United Kingdom using The Health Improvement Network. Int J Cancer. 2020; 147(9): 2394-404.
  • Arai J, Niikura R, Hayakawa Y, Kawahara T, Honda T, Hasatani K, et.al. Chemoprevention of oesophageal squamous-cell carcinoma and adenocarcinoma: a multicentre retrospective cohort study. Digestion. 2022; 103(3): 192-204.
  • Shami JJP, Zhao J, Pathadka S, Wan EYF, Blais JE, Vora P, et. al. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022; 12(2): e050510.
  • Holmberg D, Gottlieb-Vedi E, Hedberg J, Lindblad M, Mattsson F, Lagergren J. Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study. BMC Cancer. 2023; 23(1): 375.
  • Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie SH, et. al. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma. Gastric Cancer. 2022; 25(3): 652-8.
  • Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, et. al. Combination of sulindac and bexarotene for prevention of intestinal carcinogenesis in familial adenomatous polyposis. Cancer Prev Res (Phila). 2021; 14(9): 851-62.
  • Bowen CM, Deng N, Reyes-Uribe L, Parra ER, Rocha P, Solis LM, et. al. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in lynch syndrome colorectal mucosa. Front Immunol. 2023; 14: 1162669.
  • Zhang Y , Chan AT, Meyerhardt JA, Giovannucci EL. Timing of aspirin use in colorectal cancer chemoprevention: a prospective cohort study. J Natl Cancer Inst. 2021; 113(7): 841-51.
  • Figueiredo JC, Jacobs EJ, Newton CC, Guinter MA, Cance WG, Campbell PT. Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis. J Natl Cancer Inst. 2021; 113(7): 833-40.
  • Diao F, Cai S. Aspirin-based chemoprevention of colorectal cancer: the role for gut microbiota. Cancer Commun (Lond). 2020; 40(11): 633-5.
  • Tomic T, Dominguez-Lopez S, Barrios-Rodriguez R. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: a systematic review and meta-analysis. Cancer Epidemiol. 2019; 58: 52-62.
  • He P, Yang C, Ye G, Xie H, Zhong W. Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis. Colorectal Dis. 2019; 21(4): 417-26.
  • Wang Y, Wang M, Liu C, Wang W, Shi J, Dang S. Aspirin use and the risk of hepatocellular carcinoma: a meta-analysis. J Clin Gastroenterol. 2022; 56(7): e293-e302.
  • Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis c virus infection. Clin Gastroenterol Hepatol. 2020; 18(12): 2784-92 e7.
  • Liao YH, Hsu RJ, Wang TH, Wu CT, Huang SY, Hsu CY, et.al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterol. 2020; 20(1): 6.
  • Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021; 54(4): 356-67.
  • Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. Eur J Clin Pharmacol. 2022; 78(4): 647-56.
  • Marcano-Bonilla L, Schleck CD, Harmsen WS, Sadr-Azodi O, Borad MJ, Patel T, et.al. Aspirin, statins, non-aspirin nsaids, metformin, and the risk of biliary cancer: a Swedish population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2022; 31(4): 804-10.
  • Sun J, Li Y, Liu L, Jiang Z, Liu G. Aspirin use and pancreatic cancer risk: a systematic review of observational studies. Medicine (Baltimore). 2019; 98(51): e18033.
  • Ye S, Lee M, Lee D, Ha EH, Chun EM. Association of long-term use of low-dose aspirin as chemoprevention with risk of lung cancer. JAMA Netw Open. 2019; 2(3): e190185.
  • Yu SY, Ip MS, Li X, Cheung KS, Ren QW, Wu MZ, et.al. Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: a cohort study. PLoS Med. 2022; 19(1): e1003880.
  • Bittoni MA, Carbone DP, Harris RE. Ibuprofen and fatal lung cancer: a brief report of the prospective results from the third national health and nutrition examination survey (NHANES III). Mol Clin Oncol. 2017; 6(6): 917-20.
  • Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of cox-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018; 11: 721-30.
  • Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, et.al. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the epidemiology of endometrial cancer consortium. Ann Oncol. 2019; 30(2): 310-6.
  • Sperling CD, Verdoodt F, Aalborg GL, Dehlendorff C, Friis S, Kjaer SK. Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study. Int J Epidemiol. 2020; 49(1): 330-7.
  • Sperling CD, Verdoodt F, Aalborg GL, Dehlendorff C, Friis S, Kjaer SK. Non-aspirin nsaid use and mortality of endometrial cancer. a nationwide cohort study. Cancer Causes Control. 2021; 32(5): 515-23.
  • Hurwitz LM, Pinsky PF, Huang WY, Freedman ND, Trabert B. Aspirin use and ovarian cancer risk using extended follow-up of the plco cancer screening trial. Gynecol Oncol. 2020; 159(2): 522-6.
  • Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, et.al. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (nhs/nhsii): a cohort study. Lancet Oncol. 2018; 19(8): 1107-16.
  • Wield AM, Walsh CS, Rimel BJ, Cass I, Karlan BY, Li AJ. Aspirin use correlates with survival in women with clear cell ovarian cancer. Gynecol Oncol Rep. 2018; 25: 78-81.
  • Liu J, Zheng F, Yang M, Wu X, Liu A. Effect of aspirin use on survival benefits of breast cancer patients: a meta-analysis. Medicine (Baltimore). 2021; 100(33): e26870.
  • Sherman ME, Vierkant RA, Kaggal S, Hoskin TL, Frost MH, Denison L, et.al. Breast cancer risk and use of nonsteroidal anti-inflammatory agents after a benign breast biopsy. Cancer Prev Res (Phila). 2020; 13(11): 967-76.
  • Mohammed A, Miller MS, Lubet RA, Suen CS, Sei S, Shoemaker RH, et.al. Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers. Cancer Prev Res (Phila). 2020; 13(3): 273-82.
  • Fan LL, Xie CP, Wu YM, Gu XJ, Chen YH, Wang YJ. Aspirin exposure and mortality risk among prostate cancer patients: a systematic review and meta-analysis. Biomed Res Int. 2019; 2019: 9379602.
  • Skriver C, Dehlendorff C, Borre M, Brasso K, Larsen SB, Tjonneland A, et.al. Associations of low-dose aspirin or other nsaid use with prostate cancer risk in the Danish diet, cancer and health study. Cancer Causes Control. 2020; 31(2): 139-51.
  • Broadfield LA, Marcinko K, Tsakiridis E, Zacharidis PG, Villani L, Lally JSV, et.al. Salicylate enhances the response of prostate cancer to radiotherapy. Prostate. 2019; 79(5): 489-97.
  • Shaji S, Smith C, Forget P. Perioperative nsaids and long-term outcomes after cancer surgery: a systematic review and meta-analysis. Curr Oncol Rep. 2021; 23(12): 146.
There are 45 citations in total.

Details

Primary Language Turkish
Subjects Pharmacology and Pharmaceutical Sciences (Other), Clinical Sciences (Other)
Journal Section Reviews
Authors

Sıla Ölmez 0000-0002-8688-960X

Tolga Köşeci 0000-0002-8696-0525

Erkan Kozanoglu 0000-0002-0167-3384

Publication Date May 22, 2025
Submission Date November 6, 2023
Acceptance Date January 7, 2025
Published in Issue Year 2025 Volume: 15 Issue: 2

Cite

Vancouver Ölmez S, Köşeci T, Kozanoglu E. Nonsteroidal Antiinflamatuvar İlaçların Kemopreventif Etkileri. VHS. 2025;15(2):315-20.
 Download Cover Image